We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for risdiplam (Roche Products Pty Limited)
Active ingredients
risdiplam
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of 5q Spinal Muscular Atrophy (SMA)
Therapeutic area
Neurology